🎗️ Endometrial Cancer FIGO 2023 Stage (with molecular)
Assign the FIGO 2023 endometrial cancer stage from histologic aggressiveness, anatomic extent and molecular subtype (POLEmut/MMRd/p53abn/NSMP). Instant, browser-side.
Endometrial Cancer FIGO 2023 Stage (with molecular)
Histologic type
Anatomic extent
Molecular subtype
When to use
Staging and management direction for endometrial cancer under the molecular-integrated FIGO 2023 system.
How it works
Non-aggressive (G1–2 endometrioid): IA no/< ½ MI, IB ≥ ½, IIA cervical stroma, IIB substantial LVSI. Aggressive: IC confined, IIC any MI. III/IV by anatomic extension. Molecular changes early confined disease only: POLEmut → IAmPOLEmut, p53abn + MI → IICmp53abn.
Key points
- FIGO 2023 introduced histologic-aggressiveness and molecular subtype into staging — a major change from FIGO 2009.
- POLEmut confined to the corpus is downstaged to IAmPOLEmut (excellent prognosis, supports de-escalation regardless of LVSI/grade).
- p53abn confined disease with any myometrial invasion is upstaged to IICmp53abn (poor prognosis, escalate adjuvant therapy).
- MMRd and NSMP are recorded as subscripts but do not change the stage; for stage III/IV molecular subtype is recorded only.
References
Decision support for licensed clinicians only; not a substitute for clinical judgement, diagnosis or local protocols.